MedTrace Logo

Clinical Impact of Acthar in the Psoriatic Arthritis Patient (CLIPS)

NCT03419650 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2021-08-31

No results posted yet for this study

Summary

Demonstrate the clinical value of Acthar TM in patients with active Psoriatic Arthritis who lack adequate response to DMARDS, and the quantification of response by clinical, serologic and structural parameters.

Conditions

Interventions

DRUG

ACTHar

Acthar™ 80 units twice a week for 4 weeks followed by 40 units twice a week until week 12.

Sponsors & Collaborators

  • Mallinckrodt

    collaborator INDUSTRY

  • IRIS Research and Development, LLC

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-20
Primary Completion
2021-08-25
Completion
2021-08-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03419650 on ClinicalTrials.gov